- Risk of cervical cancer is not increased in Chinese carrying homozygous arginine at codon 72 of p53. Ngan, H Y S; Liu, V W S; Liu, S S // British Journal of Cancer;8/1/99, Vol. 80 Issue 11, p1828
Homozygous arginine at codon 72 (HA72) of p53 was found in 22% of normal cervices and 30.0% of cervical cancers and no significant difference was detected between normal and cervical cancer with or without HPV 16/18. There was no correlation between HA72 and risk of cervical cancer in Chinese.
- Cervical Coinfection with Human Papillomavirus (HPV) Types as a Predictor of Acquisition and Persistence of HPV Infection. Rousseau, Marie-Claude; Pereira, Joao S.; Prado, Jose C.M.; Villa, Luisa L.; Rohan, Thomas E.; Franco, Eduardo L. // Journal of Infectious Diseases;12/15/2001, Vol. 184 Issue 12, p1508
Interest in coinfection with multiple types of human papillomavirus (HPV) has increased in response to the possibility of vaccination and the discovery that the host immune response appears to be mainly type specific. This study attempts to document the occurrence of coinfec-tion with...
- Personal View. McPherson, Ann // British Medical Journal (Clinical Research Edition);1/10/1987, Vol. 294 Issue 6564, p115
Focuses on the issue of health care in Europe. Treatment of cervical cancer; Services of the National Health Services on the elderly; Increase of the revenue allocation for medical care.
- A PATIENT WITH CONFLICTING CERVICAL STUDIES. // Cortlandt Forum;3/25/2004, Vol. 17 Issue 3, p75
Presents a letter to the editor about a patient whose Pap smear revealing cervical intraepithelial neoplasia.
- Cervical screening in an inner city area: response to a call system in general practice. Shroff, Katy J.; Corrigan, Anne M.; Bosher, Melinda; Edmonds, Mary P.; Sacks, David; Coleman, Dulcie V. // BMJ: British Medical Journal (International Edition);11/19/88, Vol. 297 Issue 6659, p1317
Focuses on the development of a cervical screening call system based in general practice in London, England. Effectiveness of the system in improving the uptake of cervical screening; Analysis of practice and laboratory records before the call system; Detection of atypical cells in smears of women.
- A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix. Wit, R de; Zee, J van der; Burg, M E L van der; Kruit, W H; Logmans, A; Rhoon, G C van; Verweij, J // British Journal of Cancer;7/1/99, Vol. 80 Issue 9, p1387
We investigated the feasibility and the anti-tumour activity of weekly cisplatin and the simultaneous application of local hyperthermia in patients with a pelvic recurrence of cervical cancer in previously irradiated area. Dose levels of cisplatin 60 mg m[SUP-2], 70 mg m[SUP-2]and 80 mg...
- Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Ferrandina, G.; Lauriola, L.; Zannoni, G.F.; Distefano, M.G.; Legge, F.; Salutari, V.; Gessi, M.; Maggiano, N.; Scambia, G.; Ranelletti, F.O. // British Journal of Cancer;11/01/2002, Vol. 87 Issue 10, p1145
Investigates the relationship between cyclooxygenase-2 expression in tumor versus stroma inflammatory compartment in cervical cancer. Performance of immunostaining of tumor tissue sections with rabbit antiserum against cyclooxygenase-2; Characterization of stroma inflammatory cells in nine...
- Breast, cervical cancer program brings prevention nationwide. // Nation's Health;Nov96, Vol. 26 Issue 10, p9
Describes the expansion of the Breast and Cervical Cancer Early Detection Program throughout the United States. Approval of $102 million in funding for the program in 1997; Benefits from the use of regular mammograms; Testing for breast and cervical cancer.
- LETTERS FROM WESTMINSTER. Johnston, Philip // British Medical Journal (Clinical Research Edition);2/15/1986, Vol. 292 Issue 6518, p500
Focuses on the legislation on cervical screening in Great Britain. Plans for improving surgery facilities; Computerization of screening system; Range of policy options for breast cancer screening.